ST. LOUIS. MO – November 9, 2023 – Geneoscopy, a life sciences company focused on developing diagnostic tests for gastrointestinal health, has appointed Don Hardison to Chairman of its Board of Directors. With a career spanning over 40 years in executive leadership roles in emerging and Fortune 500 diagnostics, biotechnology, and life sciences companies, Hardison brings a wealth of experience and expertise to Geneoscopy as the company moves toward commercialization of its noninvasive, multi-target, stool RNA (mt-sRNA) colorectal cancer screening test.
“As an accomplished and respected executive in our industry, Don’s expertise and insights will be invaluable in helping steer our efforts to bring innovative, noninvasive diagnostics for gastrointestinal health to the providers and individuals who will benefit the most,” said Andrew Barnell, Chief Executive Officer and co-founder of Geneoscopy.
Having previously served as a strategic advisor to Geneoscopy before joining the board in February 2023, Hardison is well-acquainted with the company’s vision and strategy. In his expanded role as Chairman of the Board, he will provide insight and guidance as Geneoscopy prepares to commercialize its flagship product—ColoSenseTM, a noninvasive, stool-based, at-home screening test designed to detect colorectal cancer and advanced adenomas in average-risk individuals. Geneoscopy submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration for this test based on the favorable results from the pivotal CRC-PREVENT trial recently published in JAMA.
“As an advisor and board member, I have been impressed by what Geneoscopy has accomplished, and I’m honored to assume the role of Chairman of the Board at Geneoscopy during this exciting inflection point for the company,” said Hardison. “As we move forward, my primary focus will be supporting Geneoscopy’s talented leadership team by helping to guide its commercialization strategies, advance the company’s development, and drive its growth in gastrointestinal diagnostics.”
Hardison’s notable career includes serving as the President and CEO of Biotheranostics until its acquisition by Hologic in February 2021, where he played a significant role in the company’s success. Before that, he held the positions of President, CEO, and Director at Good Start Genetics. Hardison’s experience extends to his tenure as President and CEO of Exact Sciences from 2000 to 2007, where he was instrumental in taking the company public. He also held multiple senior leadership positions at Labcorp, Quest Diagnostics, and SmithKline Beecham.
About Geneoscopy, Inc.
Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Beyond colorectal cancer screening, Geneoscopy is developing tests for diagnosis, treatment selection, and therapy monitoring in other disease areas in partnership with leading universities and biopharmaceutical companies. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.
Geneoscopy Inc. Forward-Looking Statements
This release includes information about Geneoscopy’s future plans concerning its noninvasive molecular test that can detect colorectal cancer and precancerous adenomas, which constitute forward-looking statements. These forward-looking statements are based on the Company’s reasonable estimates of future results or trends. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, many of which are outside the Company’s control. Geneoscopy’s actual results and financial condition may differ materially from those in the forward-looking statements. Although the Company believes its business plans and objectives reflected in or suggested by these forward-looking statements are reasonable, such plans or objectives may not be achieved. The actual results may differ substantially from the projected result.
Media Contact
Judy Pretto
Director, Marketing Communications
815.534.0521
media@geneoscopy.com